3rd Edition of International Conference on
Neurology and Brain Disorders
- June 24-26, 2019
- Paris, France
Department of Medicine at the University of the Region of Joinville, SC, Brazil
During medical school, he performed scientific research in the areas of: Atrial Fibrillation and Stroke; Neurological Disorders in Hyperargininemia; Alzheimer's disease and the Main Aspects; Deep Brain Stimulation in Patients with Parkinson's Disease; Intestinal Dysbiosis and Multiple Sclerosis; and MicroRNAs and Multiple Sclerosis.
With medical colleagues, he described case reports on: Neuromodulation in a patient with quadriplegia; Cerebral Histoplasmosis; Temporalis Muscle Hypertrophy as a cause of Facial Pain; Wolfram Syndrome as a cause of Progressive Cerebellar Ataxia; and Pseudo-Athetosis in a patient with Multiple Sclerosis.
We will discuss about: 1) What are microRNAs; 2) How microRNAs are currently being studied in Multiple Sclerosis; 3) The relevance and demand of microRNAs as biomarkers in the disease; 4) The particularity of the effect on lymphocytes of Natalizumab therapy in the disease; 5) The changes described in microRNAs with the therapy with this drug; and 6) Future perspectives of the use of microRNAs as biomarkers of therapeutic response with this drug.
The main goal is to inspire listeners' curiosity about the study of microRNAs in Multiple Sclerosis. The perspective of the future with these molecules being possible biomarkers in different stages of the disease, may stimulate more and more researchers to study microRNAs. The possibility of using microRNAs as biomarkers of therapeutic response in Multiple Sclerosis is of major clinical interest. Many researchers and doctors may benefit in the future by discussing the topic. After all, the quality of the evaluation of the clinical response of each patient may be more precise, precocious and individualized. The discussion may benefit many patients with Multiple Sclerosis in the future. Our focus should always be to provide higher quality of life and more effective therapies for our patients.